Business
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"Urges Stockholders to Vote “FOR” the Election of Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, recently posted an investor presentation in connection with its upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on June 9, 2026. Stockholders of record as of April 22, 2026 are entitled to vote at the Annual Meeting. The presentation is available on the Pacira website at investor.pacira.com. Highlights from the presentation include:Pacira’s 5x30 strategy is delivering record financial and strategic performance. In 2025, Pacira achieved total revenue of $726.4 million, GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%1, each the highest in company history. EXPAREL volume growth accelerated to 8% in the second half of 2025, nearly doubling the first half of the year, reflecting strengthening demand and commercial execution. Since launching the 5x30 plan in January 2025, Pacira has generated total stockholder return of 22%2, demonstrating early success in translating strategy into value for all stockholders. This momentum has continued into 2026, with first quarter results demonstrating sustained growth across Pacira’s commercial portfolio, including EXPAREL revenue of $143.3 million, a 5% increase year-over-year, ZILRETTA revenue of $26.8 million, a 15% increase year-over-year and iovera° revenue of $6.2 million, a 21% increase year-over-year.Pacira has been executing a disciplined capital allocation and strategic de-risking approach designed to enhance durability and long-term growth. The Company has returned $200 million3 to stockholders since April 2025 under a $300 million share repurchase program that was authorized by the board of directors in April 2025. Pacira reached a favorable, volume-limited settlement in the multi-year EXPAREL patent litigation that secures exclusivity through 2030 and provides greater visibility into future cash flows. In parallel, Pacira is advancing PCRX-201 (enekinragene inzadenovec) and PCRX-2002, each targeting multi-billion-dollar annual market opportunities in osteoarthritis and ...